Search
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Eprodisate
go.drugbank.com/drugs/DB06405InvestigationalEprodisate slows the decline of renal function in AA amyloidosis.
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
PEV3A
go.drugbank.com/drugs/DB05144InvestigationalIt is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.
Teglarinad chloride
go.drugbank.com/drugs/DB05217InvestigationalAlthough the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalIt is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.
Tefidsogene civaparvovec
go.drugbank.com/drugs/DB16789InvestigationalIt consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes
Enpatoran
go.drugbank.com/drugs/DB16501InvestigationalIt was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327).